Medtech giant Medtronic (NYSE:MDT) touted regulatory wins in the U.S. and across the pond this week, with FDA clearance and CE Mark approval of the company’s Pacific Plus PTA catheter, the latest in the company’s portfolio of peripheral artery disease treatment devices.
The Pacific Plus PTA is a new balloon catheter with a hydrophilic coating that Medtronic offers with differently sized guidewires, sheaths and diameters. The Fridley, Minn.-based company designed the Pacific Plus PTA to work with its existing Pacific Xtreme PTA catheter.
The new device is indicated for use in different types of arteries, from renal to iliac to femoral and popliteal, and the balloon’s fast deflation may shorten surgical procedures, according to a Medtronic press release.
"The device’s ease of deliverability and various shaft lengths provide us with a flexible solution for both straightforward and complex cases," Dr. Juan Pablo Zambrano with the Jackson South Community Hospital in Miami said in the release.